237 related articles for article (PubMed ID: 24419413)
21. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
22. ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
Ni SS; Zhang J; Zhao WL; Dong XC; Wang JL
Tumour Biol; 2013 Jun; 34(3):1813-8. PubMed ID: 23475633
[TBL] [Abstract][Full Text] [Related]
23. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
[TBL] [Abstract][Full Text] [Related]
24. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
25. High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.
Wei LX; Zhou RS; Xu HF; Wang JY; Yuan MH
Tumour Biol; 2013 Apr; 34(2):941-6. PubMed ID: 23264086
[TBL] [Abstract][Full Text] [Related]
26. Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer.
Zhu X; Guo Y; Li X; Ding Y; Chen L
J Thorac Oncol; 2010 Aug; 5(8):1159-66. PubMed ID: 20661085
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway.
Zhang X; Ke X; Pu Q; Yuan Y; Yang W; Luo X; Jiang Q; Hu X; Gong Y; Tang K; Su X; Liu L; Zhu W; Wei Y
Oncotarget; 2016 Mar; 7(12):14569-85. PubMed ID: 26910912
[TBL] [Abstract][Full Text] [Related]
28. R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR.
Lan L; Wang H; Yang R; Liu F; Bi Q; Wang S; Wei X; Yan H; Su R
Life Sci; 2019 Oct; 234():116742. PubMed ID: 31401315
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC.
Xue Q; Lv L; Wan C; Chen B; Li M; Ni T; Liu Y; Liu Y; Cong X; Zhou Y; Ni R; Mao G
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1539-49. PubMed ID: 23857189
[TBL] [Abstract][Full Text] [Related]
30. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
31. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
[TBL] [Abstract][Full Text] [Related]
32. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
33. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.
Wang X; Sun Q; Chen C; Yin R; Huang X; Wang X; Shi R; Xu L; Ren B
Oncotarget; 2016 Feb; 7(7):8029-42. PubMed ID: 26771237
[TBL] [Abstract][Full Text] [Related]
34. High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma.
Zhai X; Xu L; Zhang S; Zhu H; Mao G; Huang J
Oncotarget; 2016 Jan; 7(4):4871-81. PubMed ID: 26717042
[TBL] [Abstract][Full Text] [Related]
35. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.
Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC
Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN
Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of Nemo‑like kinase promotes metastasis in non‑small‑cell lung cancer.
Shi C; Xu L; Tang Z; Zhang W; Wei Y; Ni J; Zhang S; Feng J
Oncol Rep; 2019 Sep; 42(3):1090-1100. PubMed ID: 31322229
[TBL] [Abstract][Full Text] [Related]
38. Testicular orphan nuclear receptor 4-associated protein 16 promotes non-small cell lung carcinoma by activating estrogen receptor β and blocking testicular orphan nuclear receptor 2.
Fang F; Zheng Q; Zhang J; Dong B; Zhu S; Huang X; Wang Y; Zhao B; Li S; Xiong H; Chen J; Wu N; Song SW; Chang C; Yang Y
Oncol Rep; 2013 Jan; 29(1):297-305. PubMed ID: 23129017
[TBL] [Abstract][Full Text] [Related]
39. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
[TBL] [Abstract][Full Text] [Related]
40. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.
Gürel D; Kargı A; Karaman I; Onen A; Unlü M
Pathol Oncol Res; 2012 Apr; 18(2):153-60. PubMed ID: 21681600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
